Non-Insulin-Dependent Diabetes Mellitus disease length
Item
type 2 diabetes for at least 12 months since diagnosis
boolean
C0011860 (UMLS CUI [1,1])
C0872146 (UMLS CUI [1,2])
Insulin Therapy naive
Item
insulin naive subjects
boolean
C0021641 (UMLS CUI [1,1])
C0919936 (UMLS CUI [1,2])
Oral hypoglycemic Quantity
Item
oad treatment for at least 4 months alone or combined with no more than two oads
boolean
C0359086 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
Body mass index
Item
body mass index (bmi) below 35.0 kg/m2
boolean
C1305855 (UMLS CUI [1])
Glycosylated hemoglobin A
Item
hba1c between 7.5-10.0%
boolean
C0019018 (UMLS CUI [1])
Injection U/day Willing
Item
able and willing to use twice a day injections for the entire trial period
boolean
C1828121 (UMLS CUI [1,1])
C0456683 (UMLS CUI [1,2])
C0600109 (UMLS CUI [1,3])
Thiazolidinediones
Item
current or previous treatment with thiazolidiones within the last 6 months
boolean
C1257987 (UMLS CUI [1])
Oral hypoglycemic Quantity
Item
oad treatment with three or more oads within the last 6 months
boolean
C0359086 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
Insulin regime
Item
acute insulin treatment for longer than 7 days in a row within the last 6 months
boolean
C0557978 (UMLS CUI [1])
Secondary diabetes mellitus
Item
secondary diabetes
boolean
C0271640 (UMLS CUI [1])
Maturity onset diabetes mellitus in young
Item
known maturity onset of diabetes of young (mody)
boolean
C0342276 (UMLS CUI [1])
Hypersensitivity Investigational New Drugs | Hypersensitivity Pharmaceutical Preparations Related Investigational New Drugs
Item
known or suspected allergy to trial product or related products
boolean
C0020517 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0013227 (UMLS CUI [2,2])
C0439849 (UMLS CUI [2,3])
C0013230 (UMLS CUI [2,4])